ACPU
ARCT icon

Arrowgrass Capital Partners (US)’s Arcturus Therapeutics ARCT Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,266
Closed -$1.56M – 232
2014
Q1 		$1.56M Sell
12,266
-536
-4% -$79.4K 0.06% 139
2013
Q4 		$1.61M Buy
+12,802
New +$1.61M 0.08% 127
2013
Q3 		– Sell
-26,292
Closed -$1.26M – 178
2013
Q2 		$1.26M Buy
+26,292
New +$1.29M 0.13% 79

Other funds holding ARCT

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ARCT Position: Q2 2014 in Review

Arrowgrass Capital Partners (US) sold out of Arcturus Therapeutics (ARCT) in Q2 2014, closing a stake of 12,266 shares — an estimated $1.56M sold.

Arrowgrass Capital Partners (US) first reported a position in ARCT in Q2 2013 and held it in 3 quarters. The position peaked at $1.61M in Q4 2013. 31 funds tracked by Wall St. Rank hold ARCT as of Q2 2014.

  • Arrowgrass Capital Partners (US) reported no remaining Arcturus Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 12,266 Arcturus Therapeutics shares in Q2 2014, an estimated $1.56M.
  • Arrowgrass Capital Partners (US) first reported a position in Arcturus Therapeutics in Q2 2013 and held it in 3 quarters.
  • Arrowgrass Capital Partners (US)'s Arcturus Therapeutics position peaked at $1.61M in Q4 2013.
  • 31 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2014.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2014, filed 14 Aug 2014.